Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ACV2 | ISIN: ES0167733015 | Ticker-Symbol: ORN
Tradegate
24.04.25
18:02 Uhr
2,790 Euro
+0,310
+12,50 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ORYZON GENOMICS SA Chart 1 Jahr
5-Tage-Chart
ORYZON GENOMICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,7602,85518:36
2,7902,85518:37

Aktuelle News zur ORYZON GENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18:34Oryzon Genomics - Capital raise to support long-term strategy16Oryzon has secured €30m through an equity raise (straight equity, no warrants attached) to support clinical development activities and other corporate initiatives, offering the potential to extend its...
► Artikel lesen
MoOryzon Genomics, S.A.: ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat77MADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics...
► Artikel lesen
15.04.Oryzon Genomics - First patient dosed in iadademstat + ICI SCLC trial223Oryzon Genomics has announced that the first patient has been dosed in iadademstat's Phase I/II trial, sponsored by the National Cancer Institute, (NCI) in extensive-stage small cell lung cancer (SCLC)....
► Artikel lesen
14.03.Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in March-April512BIO-Europe Spring 2025Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage...
► Artikel lesen
05.03.Oryzon Genomics, S.A.: Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat1
05.03.Oryzon (BME: ORY) publishes results of vafidemstat in PMS304Oryzon Genomics has announced the publication of a study in Frontiers in Psychiatry, which explores the potential of vafidemstat in Phelan-McDermid Syndrome (PMS). PMS is a form of autism whereby agitation...
► Artikel lesen
04.03.Oryzon Genomics - All steady heading into 2025298Oryzon has reported its FY24 results, reflecting steady progress across its pipeline. Oryzon's highest value-driving programme remains vafidemstat in borderline personality disorder (BPD), which, following...
► Artikel lesen
ORYZON GENOMICS Aktie jetzt für 0€ handeln
28.02.ORYZON GENOMICS, S.A.: ORYZON announces the voting results from its Extraordinary General Shareholders' Meeting2
27.02.Oryzon Genomics S.A. GAAP EPS of -$0.022
27.02.Oryzon Genomics, S.A.: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 202498Reshaping its Board of Directors at the upcoming Shareholders' meeting with the aim of enhancing U.S. outreachPreparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in...
► Artikel lesen
14.02.Oryzon Genomics, S.A.: ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences15
14.02.Oryzon (BME: ORY) publishes REIMAGINE results in prestigious journal348Oryzon Genomics has announced the publication of the final Phase IIa REIMAGINE results in the journal Psychiatry and Clinical Neurosciences. The REIMAGINE trial evaluated the safety and efficacy of...
► Artikel lesen
27.01.Oryzon Genomics, S.A.: ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting1
23.01.Oryzon Genomics, S.A.: ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome512Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015...
► Artikel lesen
23.01.Oryzon Genomics (BME: ORY) doses first patient in new MDS trial206Oryzon Genomics has announced that the first patient has been dosed in its new Phase Ib trial in myelodysplastic syndrome (MDS), led by the Medical College of Wisconsin. This study (NCT06502145) aims...
► Artikel lesen
10.01.Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in January-February1
30.10.24Oryzon Genomics - Q3 results recap key upcoming inflection points347Oryzon has reported its Q324 results, the highlight of which was the borderline personality disorder (BPD) programme, with the final Phase IIb PORTICO data demonstrating vafidemstat's potential to offer...
► Artikel lesen
24.10.24Oryzon Genomics, S.A.: ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024142Final data from PORTICO, global Phase IIb vafidemstat trial in BPD, presented at the 37th ECNP annual conference in SeptemberCompany moving forward with PORTICO-2 Phase III trial preparations following...
► Artikel lesen
02.10.24Oryzon Genomics - FDA aligns on Phase III BPD plans412Oryzon Genomics has confirmed the FDA's alignment with its proposed Phase III programme for vafidemstat in borderline personality disorder (BPD). Notably, the FDA acknowledged agitation and aggression...
► Artikel lesen
01.10.24Oryzon Genomics, S.A.: ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder164FDA's feedback supports the initiation of the Phase III trialAgitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indicationOryzon may use STAXI-2 Trait...
► Artikel lesen
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1